Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients

Forst T, Michelson G, Diessel S, Jahnke J, Kapitza C (2016)

Publication Type: Journal article

Publication year: 2016

Journal

Journal of Hypertension Lippincott, Williams & Wilkins

Book Volume: 34

Pages Range: 345-350

Journal Issue: 2

DOI: 10.1097/HJH.0000000000000776

Abstract

Recent studies suggest vascular benefits of dipeptidylpeptidase IV (DPP-IV) inhibition in patients with diabetes mellitus. Only little is known about potential vascular effects of DPP-IV inhibitors in nondiabetic individuals. The aim of this study was to investigate the effect of DPP-IV inhibition in a nondiabetic hypertensive population.This was a double-blinded, randomized, placebo-controlled, mechanistic study, comparing microvascular effects of the DPP-IV inhibitor linagliptin with placebo in nondiabetic individuals with a history of arterial hypertension. Twenty-one patients received 5 mg linagliptin (5 women; age 67.6 ± 6.0 years; mean ± SD), whereas 22 patients were randomized to placebo (5 women; age 64.8 ± 7.1 years).At baseline, after 6 and 12 weeks, retinal microcirculation and arterial blood pressure profiles were assessed. Moreover, blood samples were taken for the measurement of HbA1c, asymmetric dimethylarginine, C-reactive peptide, cyclic guanosinmonophosphate, transforming growth factor beta (TGF-ß1) and cystatin C. Retinal capillary perfusion increased by 23.7 ± 10.3% (mean ± SEM; P < 0.05), retinal arterial flow by 7.6 ± 0.6 (P < 0.05) and the retinal hyperemic response by 290 ± 263% (P < 0.05) during treatment with linagliptin. No change in retinal blood flow was found in the placebo group. Although blood pressure declined in both groups, a significant decline in TGF-ß1 by 9.3 ± 4.5% (P < 0.05) could only be observed in the linagliptin group. No significant change in other laboratory parameters could be observed in both groups.Our study suggests microvascular and antifibrotic effects of linagliptin in a nondiabetic, hypertensive population.

Authors with CRIS profile

Georg Michelson Department of Ophthalmology

Involved external institutions

Profil Institut für Stoffwechselforschung GmbH DE Germany (DE) Johannes Gutenberg-Universität Mainz (JGU) DE Germany (DE)

How to cite

APA:

Forst, T., Michelson, G., Diessel, S., Jahnke, J., & Kapitza, C. (2016). Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients. Journal of Hypertension, 34(2), 345-350. https://doi.org/10.1097/HJH.0000000000000776

MLA:

Forst, Thomas, et al. "Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients." Journal of Hypertension 34.2 (2016): 345-350.

BibTeX: Download